TNF-Alpha Inhibitors for Chronic Urticaria: Experience in 20 Patients

Sand, Freja Lærke; Thomsen, Simon Francis

doi:10.1155/2013/130905

Cited by 38 publications

(38 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A positive treatment effect was defined for each disease as clearance or almost clearance of the mucocutaneous manifestations during at least 3 months of therapy. A subset of the patients described herein has been published previously .…”

Section: Methodsmentioning

confidence: 99%

Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients

Sand

Thomsen

2015

Dermatol Ther

Self Cite

View full text Add to dashboard Cite

Tumor necrosis factor-alpha (TNF)-alpha inhibitors are licensed for patients with severe refractory psoriasis and psoriatic arthritis. However, TNF-alpha inhibitors have also been used off-label for various recalcitrant mucocutaneous diseases. This study aimed to evaluate the efficacy and safety of TNF-alpha inhibitors used for off-label dermatological indications. We retrospectively evaluated patient records of 118 patients treated off-label with TNF-alpha inhibitors in a dermatological university department. Patients presented with severe aphthous stomatitis/genital aphthous lesions (26), chronic urticaria (25), hidradenitis suppurativa (29), acne conglobata (11), dissecting cellulitis of the scalp (two), orofacial granulomatosis (four), sarcoidosis (four), granuloma annulare (two), granulomatous rosacea (one), granuloma faciale (one), subcorneal pustulosis (one), pyoderma gangrenosum (four), Sweet's syndrome (four), Well's syndrome (one), benign familial pemphigus (one), lichen planus (one), and folliculitis decalvans (one). A significant number of these patients went into remission during therapy with TNF-alpha inhibitors. A total of 11 patients (9%) experienced severe adverse effects during therapy. Off-label therapy with TNF-alpha inhibitors may be considered for selected patients with severe recalcitrant mucocutaneous diseases. The risk of severe adverse effects signals that a thorough benefit-risk assessment should be performed before initiating off-label treatment with TNF-alpha inhibitors for these conditions.

show abstract

Section: Methodsmentioning

confidence: 99%

Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients

Sand

Thomsen

2015

Dermatol Ther

Self Cite

View full text Add to dashboard Cite

show abstract

“…Of all patients, 39·6% were previously treated with prednisolone and 26·0% had been treated with dapsone or one or more immunosuppressant drugs such as ciclosporin A, azathioprine, mycophenolate mofetil, methotrexate and/or tumour necrosis factor (TNF) inhibitors. We have previously reported that among a subset of 25 patients with chronic urticaria who were naïve to biological drugs or who had received omalizumab, 60% obtained complete or almost complete resolution of urticaria and angioedema after onset of therapy with either adalimumab or etanercept, whereas another 15% of patients experienced a partial response to treatment with these TNF inhibitors …”

Section: Characteristics Of 154 Patients With Chronic Spontaneous Urtmentioning

confidence: 99%

Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients

2016

View full text Add to dashboard Cite

“…Studies, based on this theory, found higher TNF-α levels in CU patients, and treatments targeting TNF-α have been studied (20,21). However, some of the studies reported similar serum TNF-α levels in both CU patients and normal controls (22).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Serum Resistin Levels and Metabolic Syndrome Related Parameters in Chronic Spontaneous Urticaria

Akca¹,

Bulur²,

Saraçoğlu³

et al. 2017

tdd

View full text Add to dashboard Cite

Amaç: Kronik spontan ürtiker (KSÜ) hastalarında serum resistin düzeyi ve metabolik sendrom (MetS) ilişkisini değerlendirmek. Yöntemler: Çalışmaya 42 KSÜ hastası ve 42 sağlıklı gönüllü dahil edildi. Boy, kilo, bel çevresi ve kan basıncı ölçümleri her iki grupta da değerlendirildi. Açlık kan şekeri, serum lipid düzeyleri, resistin ve tümör nekroz faktörü-alpha (TNF-α) düzeyleri venöz kan örneklerinde değerlendirildi. MetS tanısı National Cholesterol Education Program Adult Treatment Panell III tanı kriterleri ile belirlendi. Bulgular: KSÜ hastalarının 14'ünde (%33,3) ve kontrol grubunun 5'inde (%11,9) MetS saptandı. İki grup arasında MetS varlığı açısından istatistiksel olarak anlamlı fark bulundu, p=0,037. KSÜ hastalarının serum resistin düzeyleri ortalaması 1928,31±212,85 pg/mL ve kontrol grubunun serum resistin düzeyleri ortalaması 2107,60±156,71 pg/mL olarak saptandı. Her iki grup arasında serum resistin düzeyi açısından istatistiksel anlamlı fark görülmedi. KSÜ hastalarında MetS tanısı olan hastalar ile MetS tanısı olmayan hastalar arasında ürtiker aktivite skoru, hastalık süresi, otolog serum deri testi pozitifliği, serum immünoglobulin E düzeyi, otoimmünite varlığı, serum resistin ve TNF-α düzeyi açısından farklılık görülmedi. Sonuç: Çalışmamızda KSÜ hasta grubunda MetS görülme sıklığında artış olduğu saptanmıştır. Diğer taraftan KSÜ hastaları içinde MetS'yi olan ve olmayan iki grup arasında hastalık ilişkili parametreler ile serum resistin ve TNF-α düzeyi farklılık göstermemiştir. Anahtar kelimeler: Kronik spontan ürtiker, metabolik sendrom, resistin, tümör nekroz faktörü-alfa, ürtiker aktivite skoru, otolog serum deri testi Öz AbstractObjective: To evaluate the relationship between the serum resistin levels and metabolic syndrome (MetS) in chronic spontaneous urticaria (CSU) patients. Methods: In the study 42 CSU patients and 42 healthy volunteers were included. Height, weight, waist circumference, and blood pressure measurements were assesed for both of the groups. Fasting blood sugar, serum lipid levels, resistin and tumor necrosis factor-alpha (TNF-α) levels were evaluated in the venous blood samples. The metabolic syndrome (MetS) diagnosis was determined using the National Cholesterol Education Program Adult Treatment Panel III diagnostic criteria. Results: MetS was found in 14 (33.3%) CSU patients and 5 (11.9%) control subjects. There was a statistically significant difference between the two groups (p=0.037) in terms of MetS presence. It was found that the mean serum resistin levels was 1928.31±212.85 pg/ mL in the CSU patients and 2107.60±156.71 pg/mL in the control group. There was no statistically significant difference between the groups in terms of serum resistin levels. No difference was seen between the patients with and without a diagnosis of MetS regarding the urticaria activity score, duration of the disease, autologous serum skin test positivity, serum immunoglobulin E levels, presence of autoimmunity, serum resistin and TNF-α levels. Conclusion: An increased incidence of MetS in the CSU ...

show abstract

TNF-Alpha Inhibitors for Chronic Urticaria: Experience in 20 Patients

Cited by 38 publications

References 16 publications

Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients

Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients

Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients

Evaluation of Serum Resistin Levels and Metabolic Syndrome Related Parameters in Chronic Spontaneous Urticaria

Contact Info

Product

Resources

About